{
  "updatedAt": "2026-02-07T23:19:57.293Z",
  "surveillance": {
    "lastRun": "2026-02-07T23:19:57.240Z",
    "reasoning": null
  },
  "literature": {
    "lastRun": "2026-02-07T23:19:57.269Z",
    "reasoning": "The agent reasons over ingested literature for each autonomous-agent topic (Clinical-Adjacent and Research & Discovery). Data from sources; reasoning from patterns and inferred gaps.\n\n- **Early Detection of Disease Across Species** — 23 item(s). **Reasoning:** Prioritize validation of preclinical signals and early biomarkers for clinical use.\n- **Decoding Animal Pain and Distress** — 21 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Preclinical Disease States** — 21 item(s). **Reasoning:** Prioritize validation of preclinical signals and early biomarkers for clinical use.\n- **Unexplained Recovery and Resilience** — 13 item(s). **Reasoning:** Identify protective factors and care patterns from outlier recovery cases.\n- **Microbiome–Behavior–Health Coupling** — 13 item(s). **Reasoning:** Map microbiome–behavior–health links for interventions and diet trials.\n- **Biological Timing and Treatment Response** — 17 item(s). **Reasoning:** Use timing data to optimize anesthesia, vaccination, and treatment windows.\n- **Non-Linear Dose and Response Effects** — 21 item(s). **Reasoning:** Document threshold and paradoxical responses for dosing guidelines.\n- **Emergent Effects of Complex Care Pathways** — 13 item(s). **Reasoning:** Analyze combination effects beyond single interventions.\n- **Silent or Masked Disease and Distress** — 16 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Unintended Consequences of Standard Care** — 21 item(s). **Reasoning:** Track long-term effects of common practices to refine guidelines.\n- **Unknown Biological Signals** — 21 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers.\n- **Latent Protective Mechanisms** — 22 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers.\n- **Pain Modulation Beyond Analgesics** — 21 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Hidden Costs of Normal Physiology** — 22 item(s). **Reasoning:** Quantify cumulative cost of stress and inflammation for prevention.\n- **Environmental Exposure and Sentinel Signals** — 8 item(s). **Reasoning:** Use animal sentinel data for environmental and human health early warning.\n- **Species-Specific Health Advantages** — 16 item(s). **Reasoning:** Translate extreme physiology and adaptations into medical insights.\n- **Comparative Physiology at Extremes** — 16 item(s). **Reasoning:** Translate extreme physiology and adaptations into medical insights.\n- **Genetic Intervention and Biological Integrity** — 18 item(s). **Reasoning:** Integrate gene editing and early-life effects into health and welfare assessment.\n- **Developmental Programming and Lifelong Health** — 16 item(s). **Reasoning:** Integrate gene editing and early-life effects into health and welfare assessment.\n- **Unexpected Correlations and Anomalies** — 21 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers."
  },
  "synthesis": {
    "lastRun": "2026-02-07T23:19:57.293Z",
    "reasoning": "### From surveillance\n\n**Conditions to watch (travel / zoonotic):**\n- A Strain of Multidrug-Resistant &lt;em&gt;Salmonella&lt;/em&gt; Newport — consider travel alerts or client advice.\n- Animal disease alerts — consider travel alerts or client advice.\n- Chikungunya — consider travel alerts or client advice.\n- Clade II Monkeypox — consider travel alerts or client advice.\n- Diphtheria — consider travel alerts or client advice.\n- East African Sleeping Sickness — consider travel alerts or client advice.\n- Extensively Drug-Resistant Typhoid Fever — consider travel alerts or client advice.\n- Global Dengue — consider travel alerts or client advice.\n- Global Measles — consider travel alerts or client advice.\n- Global Polio — consider travel alerts or client advice.\n\n**Opportunity:** Review new CDC notices and surface alerts for vets and one-health partners.\n\n### From literature\n\n- **Partnerships:** New one-health and cancer papers suggest collaboration and comparative oncology opportunities.\n- **Research gaps:** Case reports and literature themes point to teaching material and emerging patterns.\n- **Opportunity:** Summarize \"new this period\" for researchers and clinics.\n\n### Reasoning by autonomous-agent topic\n\nThe literature reviewer reasons over ingested data for each autonomous-agent topic (Clinical-Adjacent and Research & Discovery). Inferred opportunities:\n\nThe agent reasons over ingested literature for each autonomous-agent topic (Clinical-Adjacent and Research & Discovery). Data from sources; reasoning from patterns and inferred gaps.\n- **Early Detection of Disease Across Species** — 23 item(s). **Reasoning:** Prioritize validation of preclinical signals and early biomarkers for clinical use.\n- **Decoding Animal Pain and Distress** — 21 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Preclinical Disease States** — 21 item(s). **Reasoning:** Prioritize validation of preclinical signals and early biomarkers for clinical use.\n- **Unexplained Recovery and Resilience** — 13 item(s). **Reasoning:** Identify protective factors and care patterns from outlier recovery cases.\n- **Microbiome–Behavior–Health Coupling** — 13 item(s). **Reasoning:** Map microbiome–behavior–health links for interventions and diet trials.\n- **Biological Timing and Treatment Response** — 17 item(s). **Reasoning:** Use timing data to optimize anesthesia, vaccination, and treatment windows.\n- **Non-Linear Dose and Response Effects** — 21 item(s). **Reasoning:** Document threshold and paradoxical responses for dosing guidelines.\n- **Emergent Effects of Complex Care Pathways** — 13 item(s). **Reasoning:** Analyze combination effects beyond single interventions.\n- **Silent or Masked Disease and Distress** — 16 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Unintended Consequences of Standard Care** — 21 item(s). **Reasoning:** Track long-term effects of common practices to refine guidelines.\n- **Unknown Biological Signals** — 21 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers.\n- **Latent Protective Mechanisms** — 22 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers.\n- **Pain Modulation Beyond Analgesics** — 21 item(s). **Reasoning:** Aggregate behavior, physiology, and biomarker studies to improve recognition in stoic species.\n- **Hidden Costs of Normal Physiology** — 22 item(s). **Reasoning:** Quantify cumulative cost of stress and inflammation for prevention.\n- **Environmental Exposure and Sentinel Signals** — 8 item(s). **Reasoning:** Use animal sentinel data for environmental and human health early warning.\n- **Species-Specific Health Advantages** — 16 item(s). **Reasoning:** Translate extreme physiology and adaptations into medical insights.\n- **Comparative Physiology at Extremes** — 16 item(s). **Reasoning:** Translate extreme physiology and adaptations into medical insights.\n- **Genetic Intervention and Biological Integrity** — 18 item(s). **Reasoning:** Integrate gene editing and early-life effects into health and welfare assessment.\n- **Developmental Programming and Lifelong Health** — 16 item(s). **Reasoning:** Integrate gene editing and early-life effects into health and welfare assessment.\n- **Unexpected Correlations and Anomalies** — 21 item(s). **Reasoning:** Explore uncharacterized signals and anomalies for new biology or biomarkers.\n\n\n### From system insights\n\n- Surveillance: review new CDC travel notices for alerts.\n- Literature: review new papers for partnerships and gaps.\n- Cancer / case data / imaging: use for teaching, collaboration, or model development.\n\n### For veterinary medicine (clinic use)\n\n- **In the clinic:** Use surveillance for travel/zoonotic client advice; clinical + case_data for differentials, protocols, and CE; vet_practice (AAHA, AVMA, VIN, Merck) for guideline\n\n— truncated for display —"
  }
}